The increase lifts Nvidia’s remaining authorized repurchases to $235 billion, with the company expecting to complete the plan by the end of fiscal 2028.
Danaher’s earnings, capital returns, and R&D updates are shaping investor sentiment and signaling demand trends across the life sciences and diagnostics sector.